Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • 2012 Performance-Rayno Life Sciences Diagnostics And Tools: ILMN, NEOG, QDEL 0 comments
    Jan 3, 2013 3:21 PM | about stocks: CPHD, ILMN, NEOG, QDEL

    Rayno Diagnostics and Tools -Another Year of Outstanding Performance

    In a volatile year with a few earnings disappointments and the summer doldrums, the sector did quite well due to synergies with new drug therapies, technological innovation such as genomics and biomarkers, sales growth from new products and M&A.

    We need to find new ideas as some of our companies have been acquired, most recently GenProbe (NASDAQ:GPRO). Here are some highlights of our current diverse portfolio.

    • Abaxis (NASDAQ:ABAX) is a leading Company in point-of-care blood analysis for both human and veterinary markets. 17% sales growth is forecasted for 2013 .
    • Cardiovascular Systems (NASDAQ:CSII) is a medical device Company focused in minimally invasive treatment of vascular disease. Revenues are forecasted to hit $97M in fiscal year 2013 giving the stock a low P/S of about 3. The stock will move much higher if profitability is achieved next year.
    • Our two turnaround candidates are Alere (NYSE:ALR) and Response Genetics (NASDAQ:RGDX), our only two underperformers but both have very attractive valuations as measured by Price/Sales.
    • Illumina (NASDAQ:ILMN) up 82% YTD after an earnings miss but rallying on a Roche bid that was turned down by the Company. Rumors on a new buyout have resurfaced.The Company is a leader in genomics tools and DNA sequencing.
    • ThermoFisher (NYSE:TMO) is a new buy at $53.50 and is up over 20% since JY 25. The Company is a core life science research tools play and moving aggressively into clinical diagnostics with revenues over $12B.
    • Quidel (NASDAQ:QDEL) was a recently reiterated buy based on new product sales for infectious disease diagnostics such as C. difficile, Flu and Legionella.
    • Cepheid (NASDAQ:CPHD) is a new buy at $31.40 in October for an earnings turnaround is a leader in molecular diagnostics.
    • Neogen (NASDAQ:NEOG) stock is up 48% over one year and is a core small cap holding with diagnostic products for food and animal testing.
    • ExactSciences (NASDAQ:EXAS) and Sequenom (NASDAQ:SQNM) are emerging technology plays in genetic analysis for clinical testing.


    2012-2013   Original Price Price %   Price Price % RET    
        Recomm   Dec'10 Ret   10/2/12 1/2/13 1 yr    
    Abaxis ABAX 2/2/09 15 26.85 79   37.9 37.8 36.7    
    CardioV.Sys. CSII 11/5/10 7.15 11.66 63   11.45 13 29.7    
    Celera CRA 3/28/10 7 6.3 18   acquired        
    Cepheid CPHD 10/23/12 31.4       NEW 35.5 13    
    Exact Sci EXAS 12/10/10 5.6 5.98 6.8   11.36 11 36    
    GenProbe GPRO 2/2/09 45 58.35 30   82.55 acquired    
    Illumina ILMN 2/2/09 29 63.34 118   51.2 55.4 81.8    
    Immucor BLUD 4/5/10 20 19.83 0   acquired        
    Alere ALR 2/2/09 25 36.6 46   19.64 19 -17.7    
    MicroFluidics MFLU 7/6/10 0.77 1.34 74   acquired        
    NeoGen NEOG 7/2/10 26 41.03 58   42.8 45.6 48.8    
    Qiagen QGEN 3/15/10 21.5 19.55 -9   19 18.8 36    
    Quidel QDEL 6/16/10 12.4 14.45 16   18.65 19.9 31.3    
    ResponseG RGDX 2/3/12 1.5 NEW     1.3 1.4 -12.9    
    Sequenom SQNM 11/18/09 3.75 8.03 114   3.5 4.93 10.8    
    SeraCare SRLS 11/18/09 2.75 4.75 73   acquired        
    ThermoFish TMO 7/25/12 53.5 NEW     59.4 65 44.5    

    Disclosure: I am long CPHD, CSII, ILMN, QDEL, RGDX.

    Stocks: CPHD, ILMN, NEOG, QDEL
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.